Series C - Cleave Therapeutics
Investment Firm
Overview
Cleave Therapeutics is focused on protein homeostasis and stress pathways in cancer and neurodegeneration.
Announced Date
Aug 06, 2019
Closed on Date
Aug 08, 2019
Funding Type
Series C
Highlights
Location
United States, North America
Social
Investor Lead
U.S. Venture Partners
U.S. Venture Partners is a early_stage_venture and late_stage_venture and venture firm.
OUP (Osage University Partners)
OUP (Osage University Partners) is a early_stage_venture and late_stage_venture and post_ipo and seed and venture firm.
Celgene
No designation
5AM Ventures
5AM Ventures is a early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.
OrbiMed
OrbiMed is a debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.
Arcus Ventures
Arcus Ventures is a early_stage_venture and late_stage_venture firm.
Participant Investors
7
Round Details and Background
Cleave Therapeutics raised $12000000 on 2019-08-06 in Series C
Cleave Therapeutics is focused on protein homeostasis and stress pathways in cancer and neurodegeneration.
Company Funding History
4
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Aug 06, 2019 |  Series C - Cleave Therapeutics | 7 | - | 12.0M |
| Aug 17, 2016 | Series B - Cleave Therapeutics | 10 | - | 37.0M |
| Apr 09, 2013 | Series A - Cleave Therapeutics | 1 | - | 10.0M |
| Nov 14, 2011 | Series A - Cleave Therapeutics | 6 | - | 42.0M |
Recent Activity
There is no recent news or activity for this profile.